Impower133 sclc
Witryna16 wrz 2024 · In IMpower133, investigators assessed the safety and efficacy of the addition of atezolizumab, an inhibitor of PD-L1, versus placebo to first-line carboplatin and etoposide in four 21-day cycles, followed by a maintenance of atezolizumab versus placebo based on the initial randomization, in a 1:1 double-blind randomization of 403 … Witryna18 cze 2024 · Abstract VP5-2024: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide …
Impower133 sclc
Did you know?
Witryna11 kwi 2024 · 在我们的系统综述和nmas中，评估了es-sclc使用icis的生存获益和安全性，并探讨了最适合患者的治疗方法。 我们的研究结果显示，相比于其他icis， 斯鲁利单抗+化疗最有可能为es-sclc总人群带来更好的pfs和os生存获益，阿得贝利单抗+化疗带来更好os获益的可能性次之； Witryna11 kwi 2024 · BackgroundProgrammed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), but the survival benefit is still limited. This study aimed to evaluate the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan (IP/IC) …
Witryna18 cze 2024 · IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line carboplatin and etoposide ± atezolizumab ESMO Virtual Plenary Session date: 17-18 June 2024 Access to this content is restricted Please login with your ESMO Account Abstract Witryna25 maj 2024 · Small cell lung cancer (SCLC) is still a lethal disease. Three phase III randomized clinical trials (IMpower133, CASPIAN, and KEYNOTE-604) have highlighted the survival gain of adding immune ...
Witryna31 sty 2024 · The latest data from the IMpower 133 trial shows that maintenance therapy with atezolizumab (Tecentriq) plus carboplatin and etoposide (CP/ET) improves overall survival (OS) and progression-free... Witryna25 cze 2024 · IMpower133 is a phase III, multicentre, double-blinded, randomised placebo-controlled study evaluating the efficacy and safety of atezolizumab in combination with carboplatin and etoposide versus chemotherapy (carboplatin plus etoposide) alone in chemotherapy-naive patients with ES-SCLC.
Witryna11 lut 2024 · Gay et al. aligned IMpower133 patient data with their four subgroups and re-analyzed patient survival. Although this trial was not designed for this subset …
Witryna20 lut 2024 · Purpose: IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab … dhmc on callWitryna近三十年来，sclc——尤其是广泛期sclc诊疗最重要的进展即免疫治疗，impower133、caspian研究奠定了免疫治疗作为广泛期sclc一线治疗的地位，基于这两项临床研究的阳性结果，阿替利珠单抗和度伐利尤单抗联合化疗方案已经被国内外多部权威指南推荐为广泛 … dhmc oncoreWitryna9 wrz 2024 · SCLC领域的最新研究进展促进指南更新，免疫治疗地位进一步提升。 ... IMpower133研究中，阿替利珠单抗联合卡铂和依托泊苷联合治疗的中位总生存期（OS）为12.3个月，较单纯化疗治疗有所延长（10.3个月）。两组无进展生存期（PFS）分别为5.2个月和4.3个月（P=0.02）[2]。 dhm coagulation screenWitryna28 cze 2024 · The IMpower133 trial [NCT02763579] looked at frontline patients with ES-SCLC, randomized 1:1 to atezolizumab, a PD-L1 inhibitor, in combination with EP for 4 cycles, followed by maintenance with atezolizumab until progression versus EP in combination with placebo, followed by maintenance with placebo.2 This was a double … dhm collectors handbookWitryna17 gru 2024 · John V. Heymach, MD, PhD: For extensive stage, we’ve had 2 major positive studies that have changed the standard of care and there are still a lot of … cimarron trails normanWitryna15 lip 2024 · IMpower133 was the first major change to frontline treatment for extensive-stage small cell lung cancer in 30 or 40 years. Prior to that, going back to the 1980s and ’90s, it was chemotherapy... dhm collection roomsWitryna13 sty 2024 · IMpower133 (ClinicalTrials.gov identifier: NCT02763579 ), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant … cimarron woods portal